This Biotech Was Quietly Bought Before a $58 Per Share Takeout

1 hour ago 1

Jonathan Ponciano, The Motley Fool

Sat, March 21, 2026 astatine 6:15 PM CDT 3 min read

On February 17, 2026, FCPM III Services B.V. disclosed a bargain of 1,489,096 RAPT Therapeutics (NASDAQ:RAPT) shares, an estimated $46.24 cardinal commercialized based connected quarterly mean pricing.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, FCPM III Services B.V. accrued its involvement successful RAPT Therapeutics (NASDAQ:RAPT) by 1,489,096 shares during the 4th quarter. The estimated worth of the caller shares acquired was $46.24 million, based connected the mean unadjusted closing terms for the quarter. At quarter-end, the full worth of the presumption had risen by $53.22 million, reflecting some the trading enactment and changes successful RAPT’s stock price.

Top holdings aft the filing:
- NASDAQ: NAMS: $322.70 cardinal (42.3% of AUM)
- NASDAQ: DYN: $106.85 cardinal (14.0% of AUM)
- NASDAQ: ENGN: $86.98 cardinal (11.4% of AUM)
RAPT was acquired by GSK earlier this period for $58 per share, astir 90% the mean estimated acquisition terms per stock of astir $31 past quarter.

RAPT Therapeutics develops oral tiny molecule therapies targeting oncology and inflammatory diseases, with pb candidates RPT193 (inflammation) and FLX475 (oncology) successful objective trials.
It operates a clinical-stage biopharmaceutical concern exemplary focused connected cause discovery, development, and aboriginal commercialization; presently generates nary merchandise revenue.
It. targets patients with unmet aesculapian needs successful oncology and immunology, with superior customers expected to beryllium healthcare providers and institutions upon commercialization.

RAPT Therapeutics, Inc. is simply a clinical-stage biotechnology institution specializing successful the improvement of oral tiny molecule drugs for crab and inflammatory conditions. The company's strategy centers connected advancing caller CCR4 antagonists and kinase inhibitors done objective trials to code important unmet needs successful immunology and oncology.

This commercialized stands retired due to the fact that the full setup changed aft the buying was already done astatine quarter’s end. GSK and RAPT’s acquisition statement and closing some landed this quarter, meaning the presumption wasn’t built connected woody certainty but alternatively connected underlying condemnation successful the asset. What looked similar a clinical-stage biotech stake rapidly turned into a takeout arbitrage with a defined ceiling.

The numbers archer a cleanable story. Shares were efficaciously bought astir the low-$30 scope and past repriced to $58 per stock arsenic portion of a astir $2.2 cardinal acquisition, a adjacent 90% premium that locked successful gains astir immediately.

Strategically, GSK was acquiring ozureprubart, a late-stage anti-IgE therapy targeting nutrient allergies, a marketplace with important unmet request and ample diligent populations. That benignant of plus prime explains wherefore the woody cleared astatine specified a premium.

Within a portfolio dominated by high-conviction biotech names, this looks little similar luck and much similar process. You physique positions successful assets that could pull strategical interest, and occasionally the timeline compresses.

Read Entire Article